CTLA4 and cancer: It may be beneficial to co-administer anti-CTLA4/PD1 antibodies [39], [40] or a low dose of anti-cancer drugs such as cyclophosphamide or gemcitabine [41]–[43] to inhibit Treg- and MDSC-mediated immunosuppression, although there may be side effects of autoimmune-like disorders and bone marrow suppression.